EU Case Reports
Journal of Generic Medicines (2009) 6, 264–271. doi:10.1057/jgm.2009.16
House of Lords revisits 'Biogen' insufficiency; Novartis' fluvastatin patent obvious; High Court finds patent for slow release formulation valid but not infringed
Compiled and written by Olswang
Olswang is a UK technology law firm providing a comprehensive range of commercial legal services for companies in the pharmaceutical, biotechnology and medical device sectors.
Corporate
Private equity/VC
Public funding/IPO
UK/EU establishment
Banking and finance
Tax
Employment/labour law
Share schemes/employee incentive schemes
Competition/antitrust/regulatory
Intellectual property
Patent, design and trademark filing and prosecution (UK and EU)
Commercial exploitation and collaboration (eg R&D, MTA, NDA, CRADA, JV)
Strategic IP portfolio and advice and management
Freedom to operate/risk analysis opinions
Litigation (UK and EU)
This section summarises and comments on recent interesting judgments. It is not intended to be exhaustive, nor are the papers intended to constitute legal advice. For further information contact:
Michael Burdon
Partner and Head of Biosciences Group
Olswang
90 High Holborn
London WC1V 6XX
UK
Tel: +44 (0)20 7067 3279
Fax: +44 (0)20 7067 3999
Email: Michael.Burdon@olswang.com
Web: www.olswang.com
Michael Burdon1, Jade MacIntyre2, James Armstrong3 and Rebecca Singleton4
1is a partner at Olswang and head of the Life Sciences group.
2is a part-qualified patent attorney at Olswang.
3is a solicitor at Olswang.
4is a solicitor at Olswang.
